Hartung G, Hofheinz R D, Wein A, Riedel C, Rost A, Fritze D, Kreuser E D, Drees M, Kühnel J, Hehlmann R, Queisser W
Onkologisches Zentrum, III. Medizinische Klinik, Universitätsklinikum Mannheim der Universität Heidelberg, Mannheim.
Onkologie. 2001 Oct;24(5):457-62. doi: 10.1159/000055126.
A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium - folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump.
From 1997 to 1998, 51 patients [median age 60 (range 24-77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m(2)) and S-FA (500 mg/m(2)) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period.
1,178 administrations (median 24, range 3-54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8-11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2-22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%).
Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.
每周连续24小时输注5-氟尿嘧啶(5-FU)和亚叶酸钙(CA-FA)的疗法被证明是晚期转移性结直肠癌有效的一线治疗方法。亚叶酸钠(S-FA)是一种新剂型,与CA-FA不同,它允许在一个泵中与5-FU同时静脉给药。
1997年至1998年,5个中心招募了51例转移性结直肠癌患者[中位年龄60岁(范围24-77岁);男性38例,女性13例],接受每周一次24小时输注溶解于一个泵中的5-FU(2600mg/m²)和S-FA(500mg/m²),共6周,作为一线治疗。在2周的休息期后重复治疗周期。
研究期间共进行了1178次给药(中位次数24次,范围3-54次)。51例患者(中位随访20.2个月)中,2例(3.9%)达到完全缓解(CR),17例(33.3%)部分缓解(PR),21例(41.2%)病情无变化(NC)。11/51例(21.6%)患者出现疾病进展(PD),包括6例未完成第一个周期的患者。肿瘤进展的中位时间(TTP)为8.5个月(95%CI:5.8-11.3)。32/51例(62.7%)患者存活超过1年,中位生存期为16.5个月(95%CI:10.2-22.8)。在主要毒性反应中,13/51例(25.4%)患者出现美国国立癌症研究所常见毒性标准(NCICTC)III/IV级腹泻,6/51例(11.7%)患者出现III级手足综合征。4/51例(7.8%)患者出现III/IV级口腔炎,2/51例(3.9%)患者出现心脏毒性。
与传统的24小时5-FU+CA-FA治疗相似,S-FA联合治疗诱导了37.2%的客观缓解率,且毒性中等。然而,TTP似乎较为理想,S-FA的给药方便,同时为门诊患者节省了费用和时间。